Yoshino T, Watanabe J, Shitara K, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial. Presented at: 2022 American Society for Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1.
Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363-2376.
Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan (T-DXd; DS-DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). Presented at: 2022 American Society for Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 4006.
Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317:2392-2401.
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-1075.
Punt CJA, Bond MJG, Bolhuis K, et al. FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: phase III CAIRO5 study of the Dutch Colorectal Cancer Group. Presented at: 2022 American Society for Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA3506.
Cercek A, Lumish MA, Sinopoli JC, et al. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. Presented at: 2022 American Society for Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA5.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
Lenz H-J, Van Cutsem E, Limon ML, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40:161-170.
Verschoor YL, van den Berg J, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. Presented at: 2022 American Society for Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 3511.
Bachmayer S, Fastner G, Vaszi A, et al. Nonmetastatic pancreatic cancer. Strahlenther Onkol. 2018;194:627-637.
Zhong J, Switchenko J, Behera M, et al. Chemotherapy with or without definitive radiation therapy in inoperable pancreatic cancer. Ann Surg Oncol. 2018;25:1026-1033.
Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. Presented at: 2022 American Society for Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 4008.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hepatobiliary cancers. v.1.2022. nccn.org. Accessed August 18, 2022.
Oh D-Y, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Presented at: 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022. Abstract 378.
Hiraoka N, Nitta H, Ohba A, et al. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Human Pathology. 2020;105:9-19.
Javle M, Borad MJ, Azad N, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology. 2021;22:1290-1300.
Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419-2430.
Cortes J, Kim S-B, Chun W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:11431154.